BRCA2 p.Lys2950Asn

Variant summary

Our verdict is Likely benign.
-2 Likely Benign
-7
-6
-1
0
+5
+6
+9
+10
B
LB
VUS
LP
P
The variant received -2 classification points (ACMG Germline Pathogenicity v2019). PM2BP6_Strong

The NM_000059.4(BRCA2):c.8850G>C (p.Lys2950Asn) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant is absent from the gnomAD population database at sites with sufficient sequencing coverage. Splicing prediction tools (SpliceAI) predict no significant impact on normal splicing. Variant has been reported in ClinVar as Benign/Likely Benign (★★). Other variants at the same amino acid position have been reported in ClinVar (not pathogenic): p.K2950E: Uncertain_significance (ClinVar VariationId 2428161, 1 star); p.K2950= (synonymous): Likely_benign (ClinVar VariationId 136571, 3 stars); p.K2950N: Conflicting_classifications_of_pathogenicity (ClinVar VariationId 52692); p.K2950R: Conflicting_classifications_of_pathogenicity (ClinVar VariationId 233050); p.K2950T: Likely_benign (ClinVar VariationId 822764, 1 star) This exact variant is curated in the UniProt human variants database as Uncertain Significance; it is also listed as a COSMIC curated somatic variant.

Frequency

Genomes: not found (cov: 32)

Consequence

BRCA2
NM_000059.4 missense

Scores

10
6

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:3

Conservation

PhyloP100: 2.06

Publications

20 publications found
Variant links:
Genes affected
BRCA2 (HGNC:1101): (BRCA2 DNA repair associated) The product of this gene in involved in maintenance of genome stability. It is involved in double-strand break repair pathways during mitotic and meiotic homologous recombination and functions in protecting DNA replication forks. The encoded protein contains sites for interactions with PALB2 and EMSY and an N-terminal DNA binding domain. It also contains a RAD51 binding domain with multiple components. It has multiple BRC repeats, an alpha helix domain, oligonucleotide binding folds, and a tower-like domain. It has a nuclear localization signal and a phosphorylation site for cyclin-dependent kinase. The C-terminus of the protein can bind single-stranded and double-stranded DNA. The product of this gene interacts with multiple proteins, including RAD51. It is involved in recruiting RAD51 filaments to DNA double-strand break sites and also in cytoplasmic division. It also acts as a tumor suppressor. Mutations in this gene or decreased expression have been implicated in multiple tumor types, including breast, ovarian, pancreatic, prostate and other cancers. [provided by RefSeq, May 2026]
BRCA2 Gene-Disease associations (from GenCC):
  • BRCA2-related cancer predisposition
    Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
  • breast-ovarian cancer, familial, susceptibility to, 2
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Ambry Genetics
  • Fanconi anemia complementation group D1
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), ClinGen, Ambry Genetics
  • pancreatic cancer, susceptibility to, 2
    Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
  • sarcoma
    Inheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
  • hereditary breast ovarian cancer syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • Fanconi anemia
    Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
  • medulloblastoma
    Inheritance: AD Classification: LIMITED Submitted by: Ambry Genetics

Genome browser will be placed here

new If you want to explore the variant's impact on the transcript NM_000059.4, check out the Mutation Effect Viewer. This is especially useful for frameshift variants or if you want to visualize the effect of exon loss / intron retention.

Classification according to ACMG Germline Pathogenicity v2019

Classification was made for transcript:

Our verdict: Likely_benign. The variant received -2 points.

PM2Absent/extremely low in population databases
Absent from gnomAD (AD/XL gene) — PM2; Absent from gnomAD at well-covered site (MOI: AD+AR) (base 0.0001, raised to 0.000139 by highest known P/LP ClinVar AF 0.000139) — PM2 moderate.
BP6Reputable source reports benign
ClinVar 2-star benign — strong (BP6); ClinVar germline classification: Benign/Likely Benign, 2 star(s).

Variant Effect in Transcripts

Automated classification analysis was done for transcript: NM_000059.4. You can select a different transcript below to see updated classification assignments.

RefSeq Transcripts

BRCA2 NM_000059.4
MANE Select
HGVSc / HGVSpc.8850G>Cp.Lys2950Asn
Exon rankExon 22 of 27
missense
Prot: NP_000050.3UniProt: A0A7P0T9D7P51587
BRCA2 NM_001432077.1
HGVSc / HGVSpc.8850G>Cp.Lys2950Asn
Exon rankExon 22 of 27
missense
Prot: NP_001419006.1UniProt: A0A7P0T9D7P51587
BRCA2 NM_001406720.1
HGVSc / HGVSpc.8850G>Cp.Lys2950Asn
Exon rankExon 22 of 27
missense
Prot: NP_001393649.1UniProt: A0A8V8TPZ2

Ensembl Transcripts

BRCA2 ENST00000380152.8
TSL:5MANE Select
HGVSc / HGVSpc.8850G>Cp.Lys2950Asn
Exon rankExon 22 of 27
missense
Prot: ENSP00000369497.3UniProt: P51587
BRCA2 ENST00000544455.6
TSL:1
HGVSc / HGVSpc.8850G>Cp.Lys2950Asn
Exon rankExon 22 of 27
missense
Prot: ENSP00000439902.1UniProt: P51587
BRCA2 ENST00000530893.7
TSL:1
HGVSc / HGVSpc.8481G>Cp.Lys2827Asn
Exon rankExon 22 of 27
missense
Prot: ENSP00000499438.2UniProt: A0A590UJI7

Frequencies

Allele frequencies (AF), counts (AC/AN), homozygotes and coverage

Common (AF > 0.05 / Hom > 5)
Rare (AF ≤ 0.0001 / Hom ≤ 1)
Global population databases 3 sources
GnomAD3 genomes
Cov:32
GnomAD4 exome
Cov:31
GnomAD4 genome
Cov:32
Local & regional cohorts 1 source
Turkish Variome
AF: 0.000177
AC:1
Hom:0
AN:5178
Showing 4 sources

ClinVar

ClinVar submissions
Significance:Benign/Likely benign
Revision:criteria provided, multiple submitters, no conflicts
View on ClinVar
Pathogenic
VUS
Benign
Condition
-
-
1
Breast-ovarian cancer, familial, susceptibility to, 2 (1)
-
-
1
Hereditary breast ovarian cancer syndrome (1)
-
-
1
Hereditary cancer-predisposing syndrome (1)

Computational Scores

AlphaGenome AVI
Pathogenic23
AlphaMissense
Uncertain0.39
BayesDel_addAF
Uncertain0.035T
BayesDel_noAF
Benign-0.19
CADD
Benign22
DANN
Uncertain0.99
Eigen
Benign-0.0088
Eigen_PC
Benign-0.11
FATHMM_MKL
Uncertain0.89D
FuncVEP CTI
Pathogenic0.58
GPN-Star LLR
N/A-6.1
GPN-Star score
N/A6.1
M_CAP
Uncertain0.14D
MetaRNN
Uncertain0.59D
MetaSVM
Uncertain-0.27T
Mutation Taster
N/A71/29polymorphism
PhyloP100
Benign2.1
PrimateAI
Benign0.46T
PROVEAN
Benign-1.5N
REVEL
Uncertain0.41
Sift
Uncertain0.0010D
Sift4G
Uncertain0.0040D
VESM-3B
Benign-7.3
Showing 23 of 23 scores

Splicing Scores

Pangolin (max)
Benign0.0
SpliceAI score (max)
Benign0.0
Details are displayed if max score is > 0.2
Showing 2 of 2 scores

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.

MaveDB functional evidence

MaveDB is a public repository of laboratory assays that test the effect of thousands of variants at once — treat this as supporting research data and interpret it with great caution; it is not a clinical classification.

1 normal (RUO)
1 no calibration
Nucleotide level
Scores from sGE of BRCA2 exons 15–26 in humanized mouse embryonic stem cells
SGE of BRCA2 exons 15–26 in humanized mouse embryonic stem cells
Gene
BRCA2
Score
0.308
Classified as
No clinical calibration. Only research-use-only (RUO) calibrations exist for this assay — they are not reliable evidence; treat them with extreme caution.
BS3 moderate plusFunctionally normalRUO
ExCALIBR calibration: BS3 Moderate+ (-3)
+1 more calibration
BS3 moderate plusFunctionally normalRUO
ExCALIBR calibration (ClinVar 2018): BS3 Moderate+ (-3)
Nucleotide level
Scores from sGE of BRCA2 exons 15 to 26 in Hap1 cells
SGE of BRCA2 exons 15 to 26 in Hap1 cells
Gene
BRCA2
Score
0.134
No calibration data
This score is at approximately the 60th percentile of all variants tested in this assay.
This score has not been calibrated against ACMG evidence — shown for context only, not as clinical evidence.

Publications

Other links and lift over

For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.